Cargando…

The Impact of Concomitant Medication Use on Patient Eligibility for Phase I Cancer Clinical Trials

Concomitant medication (CM) use may result in Phase I cancer clinical trial ineligibility due to concern for potential CM-investigational drug interactions or alteration of investigational drug absorption. Few studies have examined the impact of CM use on trial eligibility. Methods: We reviewed reco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borad, Mitesh J., Curtis, Kelly K., Babiker, Hani M., Benjamin, Martin, Tibes, Raoul, Ramanathan, Ramesh K., Wright, Karen, Dueck, Amylou C., Jameson, Gayle, Von Hoff, Daniel D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2012
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434362/ https://www.ncbi.nlm.nih.gov/pubmed/22962561 http://dx.doi.org/10.7150/jca.4714

Ejemplares similares

Marantic Endocarditis Associated with Pancreatic Cancer: A Case Series
por: Jameson, Gayle S., et al.
Publicado: (2009)

Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study
por: Tibes, Raoul, et al.
Publicado: (2018)

(18)F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer
por: Korn, Ronald L., et al.
Publicado: (2017)

Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome
por: Weiss, Glen J., et al.
Publicado: (2011)

Skeletal Metastases in Pancreatic Cancer: A Retrospective Study and Review of the Literature
por: Borad, Mitesh J., et al.
Publicado: (2009)

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma
por: Babiker, Hani M, et al.
Publicado: (2017)

Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors
por: Curtis, Kelly K., et al.
Publicado: (2014)

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
por: Infante, Jeffrey R, et al.
Publicado: (2018)

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
por: Infante, Jeffrey R, et al.
Publicado: (2018)

Population‐level evidence of survival benefits of patient‐reported outcome symptom monitoring software systems in routine cancer care
por: Basch, Ethan, et al.
Publicado: (2020)

Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials
por: Bailey, Christopher H., et al.
Publicado: (2011)

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
por: Barrett, Michael T., et al.
Publicado: (2015)

Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities
por: Curtis, Kelly K, et al.
Publicado: (2011)

Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia
por: Tremblay, Douglas, et al.
Publicado: (2021)

Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
por: Tibes, Raoul, et al.
Publicado: (2014)

Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
por: Tibes, Raoul, et al.
Publicado: (2019)

18-FDG PET/CT assessment of basal cell carcinoma with vismodegib
por: Thacker, Curtis A, et al.
Publicado: (2012)

Dose–response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin
por: Lorza, Andres M. Arias, et al.
Publicado: (2020)

Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study
por: Kunzmann, Volker, et al.
Publicado: (2017)

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
por: Geyer, Holly L., et al.
Publicado: (2015)

Clinical study of genomic drivers in pancreatic ductal adenocarcinoma
por: Barrett, Michael T, et al.
Publicado: (2017)

Patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease
por: Taarnhøj, Gry A., et al.
Publicado: (2020)

Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail
por: Elhariri, Ahmed, et al.
Publicado: (2023)

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]
por: Babiker, HM, et al.
Publicado: (2019)

Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research
por: Huberty, Jennifer, et al.
Publicado: (2019)

Hepatoid Carcinoma of the Pancreas: Case Report, Next-Generation Tumor Profiling, and Literature Review
por: Chang, James M., et al.
Publicado: (2016)

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
por: Ramanathan, Ramesh K., et al.
Publicado: (2020)

Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score
por: Langlais, Blake T., et al.
Publicado: (2021)

Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic
por: Pfeiler, Georg, et al.
Publicado: (2022)

Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
por: Ramanathan, Ramesh K., et al.
Publicado: (2020)

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
por: Patnaik, A, et al.
Publicado: (2014)

Advances in systemic therapy for advanced pancreatobiliary malignancies
por: Halfdanarson, Thorvardur R, et al.
Publicado: (2013)

Oncolytic Adenoviruses in Gastrointestinal Cancers
por: Yokoda, Raquel T., et al.
Publicado: (2018)

Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
por: Conroy, Michael, et al.
Publicado: (2017)

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date
por: Uson Junior, Pedro Luiz Serrano, et al.
Publicado: (2023)

Correction to: Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
por: Lee, Minji K., et al.
Publicado: (2021)

Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
por: Lee, Minji K., et al.
Publicado: (2020)

Correction to: Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
por: Lee, Minji K., et al.
Publicado: (2023)

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
por: McKeage, Mark J, et al.
Publicado: (2012)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nc0takekgddq89lnopqiqcfj9i